Using real-world evidence to define safe pain management strategies in cirrhosis

使用现实世界的证据来定义肝硬化的安全疼痛管理策略

基本信息

  • 批准号:
    10808794
  • 负责人:
  • 金额:
    $ 18.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-15 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT Up to 80% of patients with cirrhosis experience pain—a rate that is twice as high as in the general population. Yet managing pain in cirrhosis patients is uniquely challenging due to provider concerns about adverse events related to multiple classes of analgesics, which unfortunately puts these patients at risk for undertreatment of pain. There are limited data on actual pain management strategies and analgesic-related harms in the clinically diverse population of cirrhosis patients, and consequently, minimal evidence-based guidance on how to appropriately treat pain in this population. The objective of the current proposal is to address this critical unmet need by investigating real-world utilization and harms of commonly used analgesics among patients with cirrhosis to inform the development of evidence-based guidance to support providers in managing pain in this population. With KL2 support, Dr. Rubin has created a retrospective longitudinal cohort of >500,000 Veterans with cirrhosis using national Veterans Health Administration (VHA) electronic health record (EHR) data. She will leverage this cohort to achieve the following Aims: (1) Define the epidemiology of pain management, and rates of and risk factors for analgesic-related adverse outcomes in cirrhosis; (2) Quantify the risk of major adverse outcomes in analgesic users versus nonusers; (3) Establish guiding principles for providing evidence- based pain management to cirrhosis patients through a Delphi consensus process. This work will provide essential preliminary data for a future pragmatic trial to test the impact of dissemination of this guidance on both provider practices and patient outcomes and quality-of-life. Dr. Rubin is uniquely positioned to conduct this study as a hepatologist the at the University of California, San Francisco with experience studying clinical outcomes, including pain and analgesic use, in cirrhosis patients using large datasets. Building upon a strong foundation of research support, this K23 award will establish Dr. Rubin as an independent health services researcher by providing her with formal training and experience in four essential skills for generating and translating real- world evidence: (1) effectively leveraging large EHR-based datasets, (2) pharmacoepidemiologic analysis, (2) causal inference methods, and (4) techniques for translating evidence into clinical practice. She has assembled a multidisciplinary mentorship team with expertise in hepatology and clinical outcomes research (Jennifer Lai), biostatistical and epidemiologic skills for leveraging observational data (Salomeh Keyhani), and pain management and pre-implementation/implementation methods (Karen Seal). Her scientific advisors will provide additional methodologic expertise in advanced biostatistical methods (Charles McCulloch), VHA-based epidemiologic study design (Katherine Hoggatt), and Delphi consensus methods (Rebecca Sudore). The proposed multidisciplinary team, scientific aims, and career development goals will not only foster Dr. Rubin's transition to a successful independent investigator and health services research leader within the field of hepatology, but also, more importantly, improve the care delivered to cirrhosis patients suffering from pain.
项目摘要/摘要 高达80%的肝硬化患者经历疼痛,这一比例是普通人群的两倍。 然而,由于供应商对不良事件的担忧,肝硬化患者的疼痛管理具有独特的挑战性 与多种类型的止痛药有关,这不幸地使这些患者处于治疗不足的风险中。 痛苦临床上关于实际疼痛管理策略和镇痛相关危害的数据有限。 不同人群的肝硬化患者,因此,关于如何 适当地治疗这一人群的疼痛。当前提案的目标是解决这一关键的未满足问题 通过调查患者中常用镇痛药的实际使用和危害, 肝硬化告知循证指南的发展,以支持供应商在管理疼痛, 人口在KL 2的支持下,鲁宾博士创建了一个超过50万退伍军人的回顾性纵向队列 使用国家退伍军人健康管理局(VHA)电子健康记录(EHR)数据。她 将利用这一队列来实现以下目标:(1)定义疼痛管理的流行病学, 肝硬化患者镇痛相关不良结局的发生率和风险因素;(2)量化主要 镇痛药使用者与非使用者的不良结局;(3)建立提供证据的指导原则- 通过德尔菲共识过程对肝硬化患者进行基于疼痛的管理。这项工作将提供 为未来的务实试验提供必要的初步数据,以测试本指南的传播对 提供者的做法和病人的结果和生活质量。鲁宾博士是进行这项研究的唯一人选 作为加州大学旧金山弗朗西斯科的肝病学家,他具有研究临床结果的经验, 包括疼痛和止痛药的使用。建立在坚实的基础上 这项K23奖将使鲁宾博士成为一名独立的卫生服务研究人员, 在生成和翻译真实的的四种基本技能方面为她提供了正式的培训和经验- 全球证据:(1)有效利用基于EHR的大型数据集,(2)药物流行病学分析,(2) 因果推理方法;(4)将证据转化为临床实践的技术。她有 组建了一个多学科导师团队,具有肝病学和临床结局研究方面的专业知识 (Jennifer Lai),利用观察数据的生物统计学和流行病学技能(Salomeh Keyhani),以及 疼痛管理和实施前/实施方法(Karen Seal)。她的科学顾问会 提供先进生物统计方法(Charles McCulloch)的额外方法学专业知识,基于VHA 流行病学研究设计(凯瑟琳Hoggatt)和德尔菲共识方法(丽贝卡Sudore)。的 建议的多学科团队,科学目标和职业发展目标不仅会促进鲁宾博士的 过渡到一个成功的独立调查员和卫生服务领域的研究领导者, 这不仅可以改善肝脏病学,而且更重要的是,可以改善对患有疼痛的肝硬化患者的护理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Rubin其他文献

Jessica Rubin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了